Breast Cancer Female
Conditions
Keywords
PDX
Brief summary
Patient derived xenografts (PDX) from mammary tumors are usually made from metastatic tumors. Indeed, PDX from primitive mammary tumors or after neoadjuvant treatment are still rare. However, the realization of such PDX (from primitive mammary tumors or after neoadjuvant treatment) would make it possible to have a better knowledge of the tumor heterogeneity to the therapeutic response, to explore the models of tumor evolution during metastatic progression and also observe the mechanisms of tumor resistance in the case of non-metastatic tumors. It therefore seems necessary to develop PDX from primitive tumors in order to observe firstly the success rate of PDX; on the other hand, the drift of the initial heterogeneity, measured by comparison of the histomolecular profile of the tumors with that of the PDXs. It aims to develop xenografts from tumor samples from surgical specimens of patients with triple negative or luminal B breast cancer.
Interventions
BIOLOGICALblood samples collection
Serology and genetic analyses will be performed in patients blood samples
Sponsors
Centre Jean Perrin
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE
Masking
NONE
Intervention model description
The intervention consists in the realization of additional blood samples to carry out serologies and genetic analyses
Eligibility
Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* ECOG (Eastern Cooperative Oncology Group) performance status ≤ 2 * Signature of the participation consent to the study, * Affiliation to a social security scheme * Major woman with: * metastatic triple-negative (TN) breast cancer, histologically proven before treatment and high grade, receiving neoadjuvant chemotherapy and having, after treatment, a breast residue of at least 15 mm on the specimen. The mammary residue will measure at least 15 mm on the mammography performed at the end of neoadjuvant treatment * metaplastic triple-negative (TN) breast cancer, histologically proven before treatment and high grade, treated by primary surgery with a tumor size of at least 15 mm on the specimen. * an inflammatory TN breast cancer (T4d), histologically proven prior to treatment, receiving neoadjuvant chemotherapy and having, after treatment, a breast residue of at least 15 mm on the specimen. The mammary residue will measure at least 15 mm on the mammography performed at the end of the neoadjuvant treatment. * non-metaplastic or inflammatory TN breast cancer, histologically proven prior to treatment, receiving neoadjuvant chemotherapy and having, after treatment, a mammary residue of at least 30 mm on the specimen. The mammary residue will measure at least 15 mm on the mammography performed at the end of the neoadjuvant treatment. * Luminal B breast cancer (LB), histologically proven prior to treatment, receiving neoadjuvant chemotherapy and having, after treatment, a mammary residue of at least 30 mm on the specimen. The mammary residue will measure at least 15 mm on the mammography performed at the end of the neoadjuvant treatment. * histologically proven metastatic TN or metastatic breast cancer with an operable metastasis whose residual size, after chemotherapy, is at least 10 mm on the specimen. Residual metastasis will be at least 15 mm on imaging. * Patients in a metastatic situation can be included regardless of the therapeutic line.
Exclusion criteria
* Pregnant woman * Patient deprived of liberty by court or administrative decision * In neoadjuvant situation: no neoadjuvant treatment by radiotherapy or hormone therapy * Refusal to participate in the study
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Percentage of successfull PDX | 2 years | PDX will be realized from patient tumor by transplanting a small fragment in a nude mouse. Once the tumor is enough grown up, the tumor is extracted to repeat this step 3 times until we get the fourth PDX with a successful tumor growth. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Histological subtype | 2 years and 4 months | Comparaison of initial tumor histological subtype with PDX histological subtype |
| expression of estrogen receptors | 2 years and 4 months | Comparaison of initial tumor expression of estrogen receptors with PDX expression of estrogen receptors |
| expression of progesterone receptors | 2 years and 4 months | Comparaison of initial tumor expression of progesterone receptors with PDX expression of progesterone receptors |
| expression of androgen receptors | 2 years and 4 months | Comparaison of initial tumor expression of androgen receptors with PDX expression of androgen receptors |
| tumor molecular classification | 2 years and 4 months | Comparaison of initial tumor molecular expression with PDX molecular classification (luminal A, luminal B, HER2 enriched or triple negative) |
| status of the amplification of the ERBB2 gene | 2 years and 4 months | Comparaison of initial tumor's ERBB2 gene amplification status with PDX's ERBB2 gene amplification status |
| Exome sequencing | 2 years and 4 months | Comparaison of genetic alterations between intial tumor, PDX and blood sample |
Countries
France
Contacts
CONTACTJudith PASSILDAS, PhD
PRINCIPAL_INVESTIGATORXavier DURANDO, Professor
Centre Jean Perrin
Outcome results
None listed